Close Menu

NEW YORK (GenomeWeb) – CellMax Life and IncellDx said today that they have signed an agreement to jointly develop and market circulating tumor cell tests across multiple solid tumors and indications, including personalized therapy selection and monitoring.

Under the agreement, CellMax will combine its technology for CTC isolation with IncellDx’s proprietary BioINK microfluidic reagents. Tests will be processed at CellMax's CLIA lab in Sunnyvale, California and will be jointly marketed in the US by its sales force.

Additional terms of the agreement were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.